Letter sent to Healthcare Professionals: Ondexxya (andexanet alfa)
Letter advises commercial anti-FXa activity assays are unsuitable for measuring anti-FXa activity following administration of andexanet alfa. Treatment monitoring should be based on clinical parameters indicative of appropriate response, lack of efficacy and adverse events.
Source:
Portola